StockData

BridgeBio Pharma vs Ultragenyx Pharmaceutical

BBIO and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BBIO and RARE compare

BridgeBio Pharma is the larger company, worth 9.6 times as much as Ultragenyx Pharmaceutical ($15.1B against $1.6B).

BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 17.5% for Ultragenyx Pharmaceutical).

Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBBIORARE
Size and price
Market cap$15.1B$1.6B
Share price$77.36$15.90
Change, 1 year18.9%−51.7%
Change, 5 years95.6%−79.2%
Beta (5Y)0.222.20
Employees8341,371
StockData Score
Total score39 (better)
Valuation score01 (better)
Growth score22
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/S15.9×2.2× (better)
FCF yield−2.5% (better)−31.2%
Growth
Revenue growth (TTM)167% (better)17.5%
Revenue growth, 5Y average127% (better)19.9%
Profitability
Gross margin94.3%–
Operating margin−38.5% (better)−73.6%
Net margin–−81.7%
FCF margin−39.1% (better)−68.2%
Financial health
Interest coverage−7.1×–
Current ratio2.09 (better)1.73
Altman Z-score0.13 (better)−5.29
Piotroski F-score–5
Dividends and buybacks
Buyback yield1.7%–
Shareholder yield1.7% (better)0.00%
Ownership
Held by institutions99.4%108%
Held by insiders35.6%4.0%
Insider net buying, 12 months−$84.8M−$3.8M (better)
Superinvestors holding1–
Short interest, % of float16.6%25.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.